The Role of Macrophage-Inducible C-Type Lectin in Different Stages of Chronic Liver Disease

The macrophage-inducible C-type lectin (mincle) is part of the innate immune system and acts as a pattern recognition receptor for pathogen-associated molecular patterns (PAMPS) and damage-associated molecular patterns (DAMPs). Ligand binding induces mincle activation which consequently interacts with the signaling adapter Fc receptor, SYK, and NF-kappa-B. There is also evidence that mincle expressed on macrophages promotes intestinal barrier integrity. However, little is known about the role of mincle in hepatic fibrosis, especially in more advanced disease stages. Mincle expression was measured in human liver samples from cirrhotic patients and donors collected at liver transplantation and in patients undergoing bariatric surgery. Human results were confirmed in rodent models of cirrhosis and acute-on-chronic liver failure (ACLF). In these models, the role of mincle was investigated in liver samples as well as in peripheral blood monocytes (PBMC), tissues from the kidney, spleen, small intestine, and heart. Additionally, mincle activation was stimulated in experimental non-alcoholic steatohepatitis (NASH) by treatment with mincle agonist trehalose-6,6-dibehenate (TDB). In human NASH, mincle is upregulated with increased collagen production. In ApoE deficient mice fed high-fat western diet (NASH model), mincle activation significantly increases hepatic collagen production. In human cirrhosis, mincle expression is also significantly upregulated. Furthermore, mincle expression is associated with the stage of chronic liver disease. This could be confirmed in rat models of cirrhosis and ACLF. ACLF was induced by LPS injection in cirrhotic rats. While mincle expression and downstream signaling via FC receptor gamma, SYK, and NF-kappa-B are upregulated in the liver, they are downregulated in PBMCs of these rats. Although mincle expressed on macrophages might be beneficial for intestinal barrier integrity, it seems to contribute to inflammation and fibrosis once the intestinal barrier becomes leaky in advanced stages of chronic liver disease.

[1]  S. Fleming.  The kidneys , 2020, Muir's Textbook of Pathology.

[2]  C. Strassburg,et al.  Significant reduction in heart rate variability is a feature of acute decompensation of cirrhosis and predicts 90‐day mortality , 2019, Alimentary pharmacology & therapeutics.

[3]  G. Kristiansen,et al.  Combination of CCl4with alcoholic and metabolic injuries mimics human liver fibrosis. , 2019, American journal of physiology. Gastrointestinal and liver physiology.

[4]  A. de Gottardi,et al.  Addressing Profiles of Systemic Inflammation Across the Different Clinical Phenotypes of Acutely Decompensated Cirrhosis , 2019, Front. Immunol..

[5]  J. Gisbert,et al.  Microbiota Sensing by Mincle-Syk Axis in Dendritic Cells Regulates Interleukin-17 and -22 Production and Promotes Intestinal Barrier Integrity , 2019, Immunity.

[6]  M. Arumugam,et al.  Compartmentalization of Immune Response and Microbial Translocation in Decompensated Cirrhosis , 2019, Zeitschrift für Gastroenterologie.

[7]  M. Arumugam,et al.  Circulating microbiome in blood of different circulatory compartments , 2018, Gut.

[8]  K. Reddy,et al.  Acute‐on‐Chronic Liver Failure: Getting Ready for Prime Time? , 2018, Hepatology.

[9]  J. Bernhagen,et al.  Soluble CD74 Reroutes MIF/CXCR4/AKT‐Mediated Survival of Cardiac Myofibroblasts to Necroptosis , 2018, Journal of the American Heart Association.

[10]  R. Moreau,et al.  Systemic Inflammation and Acute-on-Chronic Liver Failure: Too Much, Not Enough , 2018, Canadian journal of gastroenterology & hepatology.

[11]  J. Trebicka,et al.  Gut-Liver Axis Links Portal Hypertension to Acute-on-Chronic Liver Failure , 2018, Visceral Medicine.

[12]  C. Trautwein,et al.  Circulating CXCL10 in cirrhotic portal hypertension might reflect systemic inflammation and predict ACLF and mortality , 2018, Liver international : official journal of the International Association for the Study of the Liver.

[13]  H. Yi,et al.  Spliceosome-Associated Protein 130 Exacerbates Alcohol-Induced Liver Injury by Inducing NLRP3 Inflammasome-Mediated IL-1β in Mice. , 2018, The American journal of pathology.

[14]  C. Strassburg,et al.  Increase in liver stiffness after transjugular intrahepatic portosystemic shunt is associated with inflammation and predicts mortality , 2018, Hepatology.

[15]  Mattie S. M. Timmer,et al.  Identification and Biological Activity of Synthetic Macrophage Inducible C-Type Lectin Ligands , 2018, Front. Immunol..

[16]  Mattie S. M. Timmer,et al.  The Mincle ligand trehalose dibehenate differentially modulates M1‐like and M2‐like macrophage phenotype and function via Syk signaling , 2017, Immunity, inflammation and disease.

[17]  B. Liu,et al.  The pattern recognition receptor, Mincle, is essential for maintaining the M1 macrophage phenotype in acute renal inflammation. , 2017, Kidney international.

[18]  Xinfeng Liu,et al.  Human albumin attenuates excessive innate immunity via inhibition of microglial Mincle/Syk signaling in subarachnoid hemorrhage , 2017, Brain, Behavior, and Immunity.

[19]  Richard Moreau,et al.  Systemic inflammation in decompensated cirrhosis: Characterization and role in acute‐on‐chronic liver failure , 2016, Hepatology.

[20]  C. Strassburg,et al.  Statins improve NASH via inhibition of RhoA and Ras. , 2016, American journal of physiology. Gastrointestinal and liver physiology.

[21]  J. Trebicka,et al.  Gut microbial translocation corrupts myeloid cell function to control bacterial infection during liver cirrhosis , 2016, Gut.

[22]  P. Kamath,et al.  Acute-on-chronic liver failure in cirrhosis , 2016, Nature Reviews Disease Primers.

[23]  J. Trebicka.  Predisposing Factors in Acute-on-Chronic Liver Failure , 2016, Seminars in Liver Disease.

[24]  A. Oxenius,et al.  Tumor-necrosis factor impairs CD4+ T cell–mediated immunological control in chronic viral infection , 2016, Nature Immunology.

[25]  K. Takatsu,et al.  Isoliquiritigenin Attenuates Adipose Tissue Inflammation in vitro and Adipose Tissue Fibrosis through Inhibition of Innate Immune Responses in Mice , 2016, Scientific Reports.

[26]  C. Trautwein,et al.  Chemokine (C‐X‐C motif) ligand 11 levels predict survival in cirrhotic patients with transjugular intrahepatic portosystemic shunt , 2016, Liver international : official journal of the International Association for the Study of the Liver.

[27]  P. Boor,et al.  Seven weeks of Western diet in apolipoprotein-E-deficient mice induce metabolic syndrome and non-alcoholic steatohepatitis with liver fibrosis , 2015, Scientific Reports.

[28]  R. Fimmers,et al.  CXCL9 is a prognostic marker in patients with liver cirrhosis receiving transjugular intrahepatic portosystemic shunt. , 2015, Journal of hepatology.

[29]  T. Suganami,et al.  Pathogenesis of Non-alcoholic Steatohepatitis and Its Potential Therapeutic Strategies , 2015 .

[30]  G. Zaccherini,et al.  Role of human albumin in the management of complications of liver cirrhosis. , 2014, Journal of clinical and experimental hepatology.

[31]  Y. Inagaki,et al.  Macrophage-inducible C-type lectin underlies obesity-induced adipose tissue fibrosis , 2014, Nature Communications.

[32]  J. Nattermann,et al.  Angiotensin‐II type 1 receptor‐mediated Janus kinase 2 activation induces liver fibrosis , 2014, Hepatology.

[33]  S. Terai,et al.  Hepatic Crown-Like Structure: A Unique Histological Feature in Non-Alcoholic Steatohepatitis in Mice and Humans , 2013, PloS one.

[34]  S. Zimmer,et al.  Atheroprotection via cannabinoid receptor-2 is mediated by circulating and vascular cells in vivo. , 2011, Journal of molecular and cellular cardiology.

[35]  A. Cárdenas,et al.  Acute-on-chronic liver failure: the kidneys , 2011, Current opinion in critical care.

[36]  F. Lammert,et al.  Atorvastatin attenuates hepatic fibrosis in rats after bile duct ligation via decreased turnover of hepatic stellate cells. , 2010, Journal of hepatology.

[37]  S. Zimmer,et al.  CB1 receptor inhibition leads to decreased vascular AT1 receptor expression, inhibition of oxidative stress and improved endothelial function , 2009, Basic Research in Cardiology.

[38]  S. Akira,et al.  Direct recognition of the mycobacterial glycolipid, trehalose dimycolate, by C-type lectin Mincle , 2009, The Journal of experimental medicine.

[39]  S. Yamasaki,et al.  Mincle is an ITAM-coupled activating receptor that senses damaged cells , 2008, Nature Immunology.

[40]  T. Mueller,et al.  Comparing Microarray Versus RT‐PCR Assessment of Renal Allograft Biopsies: Similar Performance Despite Different Dynamic Ranges , 2008, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[41]  F. Nevens,et al.  Atorvastatin lowers portal pressure in cirrhotic rats by inhibition of RhoA/Rho‐kinase and activation of endothelial nitric oxide synthase , 2007, Hepatology.

[42]  J. Penninger,et al.  The adaptor protein CARD9 is essential for the activation of myeloid cells through ITAM-associated and Toll-like receptors , 2007, Nature Immunology.

[43]  X. Qin,et al.  The adaptor protein CARD9 is required for innate immune responses to intracellular pathogens , 2007, Nature Immunology.

[44]  O. Cummings,et al.  Design and validation of a histological scoring system for nonalcoholic fatty liver disease , 2005, Hepatology.

[45]  R. Wiest,et al.  Bacterial translocation (BT) in cirrhosis , 2005, Hepatology.

[46]  F. Lammert,et al.  Patients with acute on chronic liver failure display "sepsis-like" immune paralysis. , 2005, Journal of hepatology.

[47]  Wiguins Etienne,et al.  Comparison of mRNA gene expression by RT-PCR and DNA microarray. , 2004, BioTechniques.

[48]  S. Ashwal,et al.  When too much is not enough. , 1992, Pediatric annals.